Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+6.63%
$12.82
99% positive prob.
5-Day Prediction
+13.76%
$13.67
99% positive prob.
20-Day Prediction
+5.93%
$12.73
94% positive prob.
SEC 8-K filings with transcript text
Feb 24, 2026 · 98% conf.
1D
+6.63%
$12.82
5D
+13.76%
$13.67
20D
+5.93%
$12.73
8-K
0001845337false00018453372026-02-242026-02-24
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 24, 2026
(Exact name of registrant as specified in its charter)
Delaware
001-40431
83-2415215
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1800 Sierra Point Parkway, Suite 200
Brisbane, California
94005
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (650) 484-0899
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 24, 2026, Day One Biopharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the quarter and year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this report. A copy of the Company’s presentation with respect to its financial results for the quarter and year ended December 31, 2025 is attached as Exhibit 99.2 to this report. Item 7.01 Regulation FD Disclosure.
On February 24, 2026, the Company updated its corporate presentation. A copy of the updated presentation is attached as Exhibit 99.3 to this report.
The information in this Current Report on Form 8-K, including Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Current Report on Form 8-K and in the accompanying Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit Number
Description
99.1
Press release issued by Day One Biopharmaceuticals, Inc. regarding its financial results for the quarter and year ended December 31, 2025, dated February 24, 2026.
99.2
Financial Results Presentation.
99.3
Corporate Presentation.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date:
February 24, 2026
By:
/s/ Charles N. York II, M.B.A.
Charles N. York II, M.B.A. Chief Operating Officer and Chief Financial Officer
Jan 12, 2026 · 98% conf.
1D
+6.63%
$12.82
5D
+13.76%
$13.67
20D
+5.93%
$12.73
8-K
false 0001845337 0001845337 2026-01-11 2026-01-11
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (January 11, 2026)
(Exact name of registrant as specified in its charter)
Delaware
001-40431
83-2415215
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1800 Sierra Point Parkway, Suite 200 Brisbane, California
94005
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: (650) 484-0899 N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 11, 2026, Day One Biopharmaceuticals, Inc. (the “Company”) issued a press release announcing its preliminary unaudited OJEMDA net product revenue results for the fourth quarter and the year ended December 31, 2025 and cash, cash equivalents and short-term investments as of December 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1. The Company has not yet completed its financial close process for the year ended December 31, 2025. The preliminary financial metrics and results included in this Current Report on Form 8-K are estimates that have not been audited and are subject to the completion of the Company’s financial closing procedures and any adjustments. The preliminary results may differ materially from the actual results that will be reflected in the Company’s financial statements when they are completed and publicly disclosed.
Item 7.01 Regulation FD Disclosure.
On January 11, 2026, the Company also announced its 2026 upcoming priorities and milestones, including that the Company expects to complete enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial evaluating tovorafenib as a front-line therapy in patients aged up to 25 years with relapsed or refractory pediatric low-grade glioma in the first half of 2026, provide initial data from the Phase 1a clinical trial for DAY301, a PTK7-targeted antibody drug conjugate, in the second half of 2026 and advance the Emi-Le program by delivering Phase 1 clinical data by mid-2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. As previously announced, on January 12, 2026, the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference (the “JPM Conference”). A copy of the Company’s presentation materials for the JPM Conference is attached hereto as Exhibit 99.2 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibits 99.1, 99.2 and 99.3 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Current Report on Form 8-K and in the accompanying Exhibits 99.1, 99.2 and 99.3 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Press Release, dated January 11, 2026
99.2
J.P. Morgan Healthcare Conference Presentation
99.3
Corporate Presentation
104
Cover Page Interacti
Nov 4, 2025
8-K
0001845337false00018453372025-11-042025-11-04
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 04, 2025
(Exact name of registrant as specified in its charter)
Delaware
001-40431
83-2415215
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1800 Sierra Point Parkway, Suite 200
Brisbane, California
94005
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (650) 484-0899
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 4, 2025, Day One Biopharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this report. A copy of the Company’s presentation with respect to its financial results for the quarter ended September 30, 2025 is attached as Exhibit 99.2 to this report. Item 7.01 Regulation FD Disclosure.
On November 4, 2025, the Company updated its corporate presentation. A copy of the updated presentation is attached as Exhibit 99.3 to this report.
The information in this Current Report on Form 8-K, including Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Current Report on Form 8-K and in the accompanying Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit Number
Description
99.1
Press release issued by Day One Biopharmaceuticals, Inc. regarding its financial results for the quarter ended September 30, 2025, dated November 4, 2025.
99.2
Financial Results Presentation.
99.3
Corporate Presentation.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date:
November 4, 2025
By:
/s/ Charles N. York II, M.B.A.
Charles N. York II, M.B.A. Chief Operating Officer and Chief Financial Officer
This page provides Day One Biopharmaceuticals Inc. (DAWN) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on DAWN's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.